Photo taken from Vivek Subbiah/LinkedIn
Jan 12, 2024, 22:39
Vivek Subbiah: Optimizing anti–body drug conjugates and radiopharmaceuticals for precision therapy
Vivek Subbiah shared a post on LinkedIn:
“Sharing this editorial from 2021: Optimizing anti–body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology”
Read further.
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 2, 2025, 20:46
Jul 2, 2025, 20:25
Jul 2, 2025, 20:16
Jul 2, 2025, 16:01